Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma

• Published in: Haematologica (Roma) 2015-01, Vol.100 (1), p.87-90
• Main Authors: Nitta, Hideaki, Terui, Yasuhito, Yokoyama, Masahiro, Mishima, Yuko, Nishimura, Noriko, Ueda, Kyoko, Kusano, Yoshiharu, Tsuyama, Naoko, Takeuchi, Kengo, Kanda, Yoshinobu, Hatake, Kiyohiko
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - secondary; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Middle Aged; Monocytes - pathology; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2014.114934

Recently, elevated peripheral blood monocyte counts at diagnosis have been shown to be an independent marker associated with poor prognosis in patients with both non-Hodgkin and Hodgkin lymphoma. In this study, we retrospectively analyzed the data from a total of 550 patients with diffuse large B-cell lymphoma and evaluated the relationship between central nervous system relapse and absolute monocyte counts at diagnosis. Twenty-six patients developed central nervous system relapse. The central nervous system relapse-free survival rate was significantly lower in patients with the absolute monocyte counts ≥ 0.51 × 10(9)/L (87.8% versus 96.4%; P